What's changing
Three regulatory currents are converging:
- AHPRA's cosmetic injectables guidelines have moved from suggestion to enforcement. The requirement for medical practitioner consultation before injectables — not nurse-only assessment — is now treated as a baseline expectation.
- Advertising restrictions on cosmetic procedures have tightened. Before-and-after imagery, social media testimonials and influencer endorsements are all in a narrower compliance lane than three years ago.
- State-level laser licensing is being reviewed in NSW and Queensland in particular. The trend is toward more restrictive operator qualifications, not fewer.
Why this matters for franchisability
A franchise system in this category has to be designed so that every venue can comply without the founder hovering. If the regulatory burden requires founder-level expertise at each clinic, the model isn't scalable — and shouldn't be franchised.
The franchisors who will survive the tightening are the ones building:
- A medical director structure that gives every clinic prescribing oversight without needing a medical practitioner physically present every hour
- Standardised clinical SOPs that match or exceed AHPRA expectations across all venues
- An advertising approval workflow at brand level — no franchisee posts anything client-facing without compliance review
- Continuing professional development that's documented and audit-defensible
The investor implications
Franchisees buying into medical aesthetics need to understand: they are buying into a regulated profession, not a beauty business. The 2026 prospect coming in with a beauty-salon background and expecting an injectable-led franchise will be the wrong fit. The 2026 prospect coming in with a nursing or medical background, or with capital plus a registered medical director recruitment plan, is the right fit.
This is reshaping franchisor recruitment. The pool is smaller. The qualifications are higher. The franchisee fee tolerance is also higher — investors with this background have realistic expectations of the capital required.
A current example of doing it right
Lermont operates two medical aesthetics clinics in Sydney's Haymarket — a Japanese-style operating model with twelve treatment categories across the two sister brands. Their decision early on was to build the clinical-governance scaffolding first, and the scale plan second. They have a medical director structure, documented SOPs that would survive an AHPRA audit, and an advertising compliance workflow. That's the work that makes them franchisable at all in 2026.
It's also the work that takes longer. There is no shortcut to clinical compliance scaffolding.
What we're advising
For founders in this category considering franchising in 2026:
- Build for the regulation that's coming, not the regulation that's here. The trend is one-directional toward more oversight.
- Don't over-rely on injectable revenue. Concepts with diversified treatment categories — laser, skin, body, recovery — have more durable unit economics if injectables are restricted further.
- Hire your compliance lead before your first franchisee. Retroactive compliance is more expensive than designed-in compliance.
The broader pattern
Medical aesthetics is following the same regulatory arc that pharmacy, optical and audiology have followed over the last two decades. The category professionalises, the operator qualifications rise, the franchisor's compliance role grows. The good news: well-regulated categories produce more durable franchise networks. The networks that survive tightening are usually the long-term winners.
If you're building in this category
This is the most regulated work we do, and the most rewarding when it's done right. Start a conversation.